Negative News SentimentNegative NewsNASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis $1.70 -0.03 (-1.45%) As of 03:14 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About XBiotech Stock (NASDAQ:XBIT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XBiotech alerts:Sign Up Key Stats Today's Range$1.68▼$1.7350-Day Range$1.73▼$2.2952-Week Range$1.68▼$2.73Volume38,950 shsAverage Volume43,367 shsMarket Capitalization$51.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XBiotech is a biopharmaceutical company based in Austin, Texas, that discovers and develops antibody-based therapies. Its approach uses “True Human” antibodies derived from naturally occurring human immune responses, with the goal of developing treatments for serious diseases. The company’s research has included antibody candidates for cancer and inflammatory conditions. One of its best-known candidates is bermekimab, an antibody that targets interleukin-1 alpha, a protein involved in inflammation. XBiotech has also pursued other therapeutic programs as part of its drug-development work. Founded in 2005, XBiotech conducts research and clinical development to advance its antibody therapies. John Simard founded the company and has served as its chief executive officer.AI Generated. May Contain Errors. Read More XBiotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreXBIT MarketRank™: 0.89439214081 of 5 starsXBiotech scored higher than 18% of companies evaluated by MarketBeat, and ranked 1583rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXBiotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXBiotech has only been the subject of 1 research reports in the past 90 days.Read more about XBiotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XBiotech is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XBiotech is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXBiotech has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.31% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 2.64, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XBiotech has recently increased by 4.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXBiotech does not currently pay a dividend.Dividend GrowthXBiotech does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News SentimentXBiotech has a news sentiment score of -3.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.Search InterestOnly 1 people have searched for XBIT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $711,251.00 in company stock, which represents 1.3642% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, XBiotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $711,251.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders21.10% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XBiotech's insider trading history. Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XBIT Stock News HeadlinesXBiotech (NASDAQ:XBIT) Director John Simard Purchases 368,524 Shares of StockOctober 29, 2026 | insidertrades.comXBiotech Inc.: XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive OfficersOctober 23, 2026 | finanznachrichten.deThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 19 at 1:00 AM | Porter & Company (Ad)XBiotech Appoints Jan-Paul Simard as Co-Chief Executive Officer Alongside Dr. Sushma ShivaswamyOctober 23, 2026 | quiverquant.comQXBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive OfficersOctober 23, 2026 | globenewswire.comXBiotech Inc.: XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal CancerOctober 19, 2026 | finanznachrichten.deXBiotech's TASKIN Trial Meets Primary Efficacy Criterion In Metastatic Colorectal CancerOctober 19, 2026 | rttnews.comXBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal CancerOctober 19, 2026 | finance.yahoo.comSee More Headlines XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed this year? XBiotech's stock was trading at $2.39 on January 1st, 2026. Since then, XBIT shares have decreased by 28.5% and is now trading at $1.71. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) posted its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.02 by $0.17. When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. Who are XBiotech's major shareholders? Top institutional shareholders of XBiotech include State Street Corp (0.24%) and Allworth Financial LP (0.11%). View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Palantir Technologies (PLTR), Plug Power (PLUG) and PayPal (PYPL). Company Calendar Last Earnings11/12/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (29m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 XBIT's financial health is in the Red zone, according to TradeSmith. XBIT has been in this zone for over 29 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XBIT CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees87Year Founded2005Profitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-33.03% Return on Assets-31.57% Debt Debt-to-Equity RatioN/A Current Ratio39.51 Quick Ratio33.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book0.42Miscellaneous Outstanding Shares30,490,000Free Float24,055,000Market Cap$51.71 million OptionableOptionable Beta0.76 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:XBIT) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.